These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 27743068

  • 21. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
    Mori T, Crandall CJ, Ganz DA.
    Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
    Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ.
    J Clin Densitom; 2006 Feb; 9(2):133-43. PubMed ID: 16785071
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B.
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
    Su Y, Lai FTT, Yip BHK, Leung JCS, Kwok TCY.
    Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
    [Abstract] [Full Text] [Related]

  • 25. Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?
    Gajic-Veljanoski O, Bayoumi AM, Tomlinson G, Khan K, Cheung AM.
    Osteoporos Int; 2012 Nov; 23(11):2681-92. PubMed ID: 22398856
    [Abstract] [Full Text] [Related]

  • 26. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
    Nayak S, Roberts MS, Greenspan SL.
    PLoS One; 2012 Nov; 7(3):e32879. PubMed ID: 22427903
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
    Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE.
    J Bone Miner Res; 2013 Feb; 28(2):395-403. PubMed ID: 22991163
    [Abstract] [Full Text] [Related]

  • 28. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O, Jönsson B, Kanis JA.
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C, Nanagara R, Songpatanasilp T, Unnanuntana A.
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ, Bauer DC, Ensrud KE.
    JAMA; 2007 Aug 08; 298(6):629-37. PubMed ID: 17684185
    [Abstract] [Full Text] [Related]

  • 31. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR, Lier DA, Hanley DA, Juby AG, Beaupre LA, STOP-PRIHS Team.
    Osteoporos Int; 2017 Jun 08; 28(6):1965-1977. PubMed ID: 28275838
    [Abstract] [Full Text] [Related]

  • 32. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
    Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ.
    Osteoporos Int; 2005 Dec 08; 16(12):1883-93. PubMed ID: 16133649
    [Abstract] [Full Text] [Related]

  • 33. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K, Blinder VS, Elkin EB.
    J Clin Oncol; 2012 May 01; 30(13):1468-75. PubMed ID: 22370313
    [Abstract] [Full Text] [Related]

  • 34. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 May 01; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN, Burge RT, Marshall DA, Lindsay R.
    Am J Manag Care; 2008 Sep 01; 14(9):605-15. PubMed ID: 18778176
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
    Sowa PM, Downes MJ, Gordon LG.
    J Bone Miner Metab; 2017 Mar 01; 35(2):199-208. PubMed ID: 26969395
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
    Ito K.
    JAMA Netw Open; 2020 Dec 01; 3(12):e2027584. PubMed ID: 33258906
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.